|
|
Volumn 3, Issue 1, 2002, Pages 12-30
|
|
Drug policy: making effective drugs available without bankrupting the healthcare system.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ESSENTIAL DRUG;
CANADA;
COST BENEFIT ANALYSIS;
DRUG CONTROL;
DRUG COST;
DRUG SURVEILLANCE PROGRAM;
ECONOMICS;
EVIDENCE BASED MEDICINE;
HEALTH CARE DELIVERY;
HEALTH CARE POLICY;
HUMAN;
MANAGEMENT;
MARKETING;
MEDICAL LITERATURE;
ORGANIZATION AND MANAGEMENT;
PHARMACOEPIDEMIOLOGY;
POSTMARKETING SURVEILLANCE;
PUBLIC HEALTH;
REIMBURSEMENT;
REVIEW;
SAFETY;
STANDARD;
ADVERSE DRUG REACTION REPORTING SYSTEMS;
CANADA;
COST-BENEFIT ANALYSIS;
DRUG AND NARCOTIC CONTROL;
DRUG COSTS;
DRUGS, ESSENTIAL;
EVIDENCE-BASED MEDICINE;
HEALTH POLICY;
HEALTH SERVICES ACCESSIBILITY;
HUMANS;
MARKETING;
NATIONAL HEALTH PROGRAMS;
ONTARIO;
PHARMACOEPIDEMIOLOGY;
PHARMACOPOEIAS;
POLICY MAKING;
PRODUCT SURVEILLANCE, POSTMARKETING;
REIMBURSEMENT MECHANISMS;
SAFETY;
MLCS;
MLOWN;
|
|
EID: 0141671978
PISSN: 1488917X
EISSN: None
Source Type: Journal
DOI: 10.12927/hcpap.2002.16906 Document Type: Review |
|
Times cited : (14)
|
|
References (46)
|
